蛋白质二硫化异构酶4是内皮功能和生存的重要调节剂
Shuhan Bu1, Aman Singh1, Hien C Nguyen1,2
1Department of Medical Biophysics, Schulich School of Medicine and Dentistry, University of Western Ontario, 1151 Richmond St. N., London, ON N6A 3K7, Canada.
International journal of molecular sciences
|April 13, 2024
概括
内皮细胞中蛋白二硫化异构酶4 (PDIA-4) 的损失会损害自和功能,通过TGFβ信号促进内皮细胞向介质细胞的过渡. 这揭示了PDIA-4.
科学领域:
- 内皮细胞生物学 内皮细胞生物学
- 自研究的研究自.
- 细胞过渡的分子机制.
背景情况:
- 内皮细胞自对于维持内皮细胞功能至关重要.
- 减少蛋白二硫化异构酶4 (PDIA-4) 表达与抑制内皮细胞自有关,但其具体作用尚不清楚.
研究的目的:
- 为了研究PDIA-4在内皮细胞中的功能.
- 确定PDIA-4损失对内皮细胞自,功能和潜在转变的影响.
主要方法:
- 产生的内皮细胞特异性PDIA-4淘汰模型.
- 评估了自流,内皮功能标志物,细胞亡和细胞结构.
- 研究了TGFβ信号在PDIA-4沉默细胞中的作用.
主要成果:
- 内皮细胞特异性PDIA-4损失损害了自流,导致内皮功能障碍和亡.
- 由于PDIA-4缺乏,导致内皮细胞转化为介质酶 (EndMT),其特征是细胞结构和标记体表达的改变.
- 失去PDIA-4激活了TGFβ信号,该信号负责调解EndMT.
结论:
- PDIA-4对于维持内皮细胞自和功能至关重要.
- 由于PDIA-4缺乏,通过TGFβ信号激活促进EndMT.
- PDIA-4代表了调节内皮功能和预防EndMT的潜在治疗标.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
Protein Modifications in the RER
5.1K
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
5.1K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.2K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K
Dipeptidyl Peptidase 4 Inhibitors
182
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182


